Sirion gains license to ophthalmic emulsion

Tampa, FL-Sirion Therapeutics Inc. agreed to receive exclusive U.S. licensing rights to a topical ophthalmic emulsion containing difluprednate, a steroid compound that may treat inflammatory eye diseases.

"We are excited about the potential that this product brings to Sirion," said Roger Vogel, MD, chief medical officer of Sirion. "We believe this strong steroid can fill a gap in the current treatment options for moderate and severe inflammatory diseases of the eye."

Under the agreement, Senju Pharmaceuticals will give Sirion rights to develop, use, obtain governmental approval, manufacture, sell, distribute, and promote difluprednate formulations as an ophthalmic emulsion and/or suspension throughout the United States.